Secondary analyses of the effects of lutein/zeaxanthin on age-related macular degeneration progression: AREDS2 report No. 3.

@article{Chew2014SecondaryAO,
  title={Secondary analyses of the effects of lutein/zeaxanthin on age-related macular degeneration progression: AREDS2 report No. 3.},
  author={Emily Y. Chew and Traci E Clemons and John SanGiovanni and Ronald P. Danis and Frederick L. Ferris and Michael J. Elman and Andrew N. Antoszyk and Alan J. Ruby and David Orth and Susan B. Bressler and Gary Edd Fish and George Baker Hubbard and Michael L. Klein and Suresh R. Chandra and B{\'a}rbara A. Blodi and Amitha Domalpally and Thomas R. Friberg and Wai T. Wong and Philip J. Rosenfeld and Elvira Agr{\'o}n and Cynthia A. Toth and Paul S. Bernstein and Robert D. Sperduto},
  journal={JAMA ophthalmology},
  year={2014},
  volume={132 2},
  pages={
          142-9
        }
}
IMPORTANCE The Age-Related Eye Disease Study (AREDS) formulation for the treatment of age-related macular degeneration (AMD) contains vitamin C, vitamin E, beta carotene, and zinc with copper. The Age-Related Eye Disease Study 2 (AREDS2) assessed the value of substituting lutein/zeaxanthin in the AREDS formulation because of the demonstrated risk for lung cancer from beta carotene in smokers and former smokers and because lutein and zeaxanthin are important components in the retina. OBJECTIVE… CONTINUE READING
BETA

Citations

Publications citing this paper.
SHOWING 1-10 OF 53 CITATIONS

References

Publications referenced by this paper.
SHOWING 1-10 OF 39 REFERENCES

Long - term effects of vitamins C and E , β - carotene , and zinc on age - relatedmacular degeneration : AREDS report no . 35

  • JP SanGiovanni, EY Chew, TE Clemons
  • Ophthalmology
  • 2013

Similar Papers

Loading similar papers…